RENB Renovaro Biosciences Inc
Price (delayed)
$0.524
Market cap
$83.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.89
Enterprise value
$86.77M
enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and
Highlights
The debt has declined by 17% year-on-year
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
Renovaro Biosciences's quick ratio has shrunk by 63% YoY but it has surged by 50% QoQ
Renovaro Biosciences's net income has plunged by 200% YoY and by 40% from the previous quarter
Key stats
What are the main financial stats of RENB
Market
Valuations
Earnings
Shares outstanding
158.72M
Market cap
$83.17M
Enterprise value
$86.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.79
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$126.09M
Net income
-$123.46M
EBIT
-$122.36M
EBITDA
-$122.23M
Free cash flow
-$10.28M
Per share
Balance sheet
Liquidity
EPS
-$0.89
EPS diluted
-$0.89
Free cash flow per share
-$0.06
Book value per share
$0.66
Revenue per share
$0
TBVPS
$0.02
Total assets
$121.83M
Total liabilities
$23.75M
Debt
$3.82M
Equity
$98.09M
Working capital
-$21.09M
Debt to equity
0.04
Current ratio
0.08
Quick ratio
0.06
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-94.8%
Return on equity
-121%
Return on invested capital
N/A
Return on capital employed
-123.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RENB stock price
How has the Renovaro Biosciences stock price performed over time
Intraday
4.67%
1 week
-22.27%
1 month
-46.67%
1 year
-81.42%
YTD
-37.28%
QTD
-3.53%
Financial performance
How have Renovaro Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$126.09M
Net income
-$123.46M
Gross margin
N/A
Net margin
N/A
Renovaro Biosciences's net income has plunged by 200% YoY and by 40% from the previous quarter
RENB's operating income has shrunk by 54% QoQ
Growth
What is Renovaro Biosciences's growth rate over time
Valuation
What is Renovaro Biosciences stock price valuation
P/E
N/A
P/B
0.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 25% YoY but it rose by 2.2% QoQ
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
The stock's P/B is 71% below its last 4 quarters average of 2.6 and 61% below its 5-year quarterly average of 1.9
Efficiency
How efficient is Renovaro Biosciences business performance
RENB's ROE has dropped by 66% year-on-year and by 22% since the previous quarter
The ROA has plunged by 58% YoY and by 22% from the previous quarter
Dividends
What is RENB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RENB.
Financial health
How did Renovaro Biosciences financials performed over time
The company's total liabilities has surged by 120% YoY but it fell by 24% QoQ
RENB's total assets has soared by 112% YoY but it is down by 25% QoQ
The debt is 96% smaller than the equity
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
The debt to equity has dropped by 60% year-on-year but it has increased by 33% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.